Latest news
Ionis Pharmaceuticals Q2 2026 Earnings: 36.66% EPS Beat Signals Cost Discipline, Yet Shares Slip 2.83% - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 22:35:41 GMTCLRB Q1 2026 Earnings: 32.4% EPS Beat Signals Cost Discipline Amid Pipeline Progress - Financial Summary - dars.gov.etdars.gov.et · Sun, 02 Aug 2026 07:00:00 GMTCOYA Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline in Pre-Revenue Stage - Earnings Quality Score - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 08:45:43 GMTFATE Q1 2026 Earnings: EPS Beat of 8.96% Signals Disciplined Cost Control Amid No Revenue - Strong Earnings Momentum - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 07:00:00 GMTSTIM Q1 2026 Earnings: 15.16% EPS Surprise Signals Improved Cost Discipline - Banking Earnings Report - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 07:00:00 GMTFATE Q1 2026 Earnings: EPS Beat of 8.96% Signals Disciplined Cost Control Amid No Revenue - Negative Surprise Momentum - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 06:34:16 GMTUSAR Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Disciplined Cost Management in Rare Earth Buildout - Revenue Inflection Point - dars.gov.etdars.gov.et · Sat, 01 Aug 2026 03:45:42 GMTUSAR Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Disciplined Cost Management in Rare Earth Buildout - Profit Margin Analysis - dars.gov.etdars.gov.et · Fri, 31 Jul 2026 07:00:00 GMT